Wednesday, June 2, 2010

This month's Robert Wood Johnson Foundation Clinical Scholars Health Policy Podcast guest is Aaron Kesselheim, MD, JD, MPH, a patent attorney, general internist and health services researcher from Harvard Medical School, and also a member of the PHLR National Advisory Commitee.

In a fast-paced and timely interview, Kesselheim speaks with host Matthew Press, MD, about what health care reform will mean for drug development and drug patent policy. Kesselheim also weighs in on the recent scrutiny of pharmaceutical marketing practices and why the ancient drug colchicine is making new headlines.

Kesselheim is an Instructor in Medicine at Harvard Medical School and an Associate Physician in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital. He is the recipient of the 2010 Alice S. Hersh New Investigator Award from AcademyHealth.